Last Updated: September 24, 2026

BIORPHEN Drug Patent Profile

Name: BIORPHEN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Biorphen, and what generic alternatives are available?

Biorphen is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.

The generic ingredient in BIORPHEN is phenylephrine hydrochloride. There is one drug master file entry for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Biorphen

A generic version of BIORPHEN was approved as phenylephrine hydrochloride by HIKMA on December 20^th, 2012.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for BIORPHEN?
What are the global sales for BIORPHEN?
What is Average Wholesale Price for BIORPHEN?

Summary for BIORPHEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Drug Prices:	Drug price information for BIORPHEN
What excipients (inactive ingredients) are in BIORPHEN?	BIORPHEN excipients list
DailyMed Link:	BIORPHEN at DailyMed

Drug patent expirations by year for BIORPHEN

Pharmacology for BIORPHEN

Drug Class	alpha-1 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha1-Agonists

US Patents and Regulatory Information for BIORPHEN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	BIORPHEN	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	212909-001	Oct 21, 2019	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dr Reddys Labs Sa	BIORPHEN	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	212909-002	Mar 11, 2021		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.